Pfizer's bladder cancer therapy meets main goal in late-stage study
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...
FierceBiotech3d
Pfizer's PD-1 prospect beats age-old incumbent in phase 3 bladder cancer trial
Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...
Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial
Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...
BioSpace2d
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Armed robbery in Revesby1d
Pfizer's Sasanlimab Boosts Survival in Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...
BioPharma Dive3d
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets
Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...
Reuters2d
Pfizer's bladder cancer therapy meets main goal in late-stage study
Jan 10 (Reuters) - Pfizer's (PFE.N), opens new tab experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications ...
U.S. News & World Report3d
Pfizer's Bladder Cancer Therapy Meets Main Goal in Late-Stage Study
Pfizer's Bladder Cancer Therapy Meets Main Goal in Late-Stage Study (Reuters) -Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained ...